Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to track progress in biomedical research and to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of the emerging scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of top scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche, dedicated to three main topics: neurosciences, endocrinology and cancer science. Moreover the Fondation IPSEN has started several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the science journals Cell and Science. Over the last 30 years, the Fondation IPSEN has organized over 250 meetings and produced several hundreds publications; more than 250 scientists and biomedical researchers have been awarded prizes and research grants.

Senior Vice-President
Chief Medical Officer
Ipsen Pharma, acting Fondation IPSEN Chairman

Director of Operations

Project Manager

Yannick TANGUY
Project Manager

Dominique COUZY

The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science ( as well as Science Translational Medicine (, Science Signaling (www., and Science Advances ( AAAS was founded in 1848, and includes some 261 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million.
The non-profit AAAS ( is open to all and fulfills its mission to “advance science and serve society” not only by publishing the very best scientific research but also through initiatives in science policy, international programs and science education.
Science Translational Medicine was launched in October 2009. The goal of Science Translational Medicine is to promote human health by providing a forum for communicating the latest biomedical research findings from basic, translational, and clinical researchers from all established and emerging disciplines relevant to medicine.
Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the translation of this knowledge into effective new treatments and health measures has been slow. This paradox illustrates the daunting complexity of the challenges faced by translational researchers as they apply the basic discoveries and experimental approaches of modern science to the alleviation of human suffering. A major goal of Science Translational Medicine is to publish papers that identify and fill the scientific knowledge gaps at the junction of basic research and medical application in order to accelerate the translation of scientific knowledge into new methods for preventing, diagnosing and treating human disease.

AAAS/ Science Translational Medicine

AAAS/ Science
Deputy Editor, Research

The Institute of Molecular and Cell Biology (IMCB) was launched on 23 January 1985, with the official opening ceremony held on 2 October 1987 at the National University of Singapore (NUS), to develop and support the biomedical R&D capabilities in Singapore. It subsequently became an autonomous research institute (RI) of the Agency for Science, Technology and Research (A*STAR), moving to Biopolis in 2004.

IMCB’s original vision was to foster a vibrant research culture to enable cutting edge discoveries and nurture high-quality talent. The creation and development of IMCB has catalyzed the transformation of Singapore into an international hub for biomedical research, development & innovation by:

1.  fostering the biomedical research culture in Singapore
2.  placing Singapore onto global map of scientific excellence
3.  training & recruiting capable people at all levels
4.  facilitating the development of other research entities

Over the years, IMCB has:
1.  trained more than 250 PhDs
2.  recruited more than 800 PhDs from the international community
3.  published over 2,500 research papers in top international peer-reviewed journals, with a yearly citation above 8,000 since 2012
4. established numerous collaborations with industrial, clinical & academic partners, both locally and internationally

Our mission is to:
1.  conduct cutting-edge discovery research in disease pathways
2.  groom early career researchers to be future leaders in their fields
3.  collaborate with medical & industry communities for research impact

IMCB’s Discovery research comprises 5 major programmes:
1.  Cancer Cell Signalling
2.  Epigenetics and Diseases
3.  iPS cell and Regenerative Medicine
4.  Multi-Modal Molecular (M3) Biology
5.  Technology and Translation

Research Director

Wanjin HONG
Professor and Executive Director

June Hui Xiang OH

PhD student

Esther Meimei LUO